Vizual Stocks works best vertically on mobile.
VizualStocks APIOperating KPI and segment definitions available for AMGEN (AMGN) through the VizualStocks API.
Worldwide product sales of Aranesp, Amgen's treatment for anemia caused by chronic kidney disease and for anemia in certain cancer patients receiving myelosuppressive chemotherapy.
aranespRevenueWorldwide product sales of BLINCYTO, Amgen's therapy for CD19-positive B-cell acute lymphoblastic leukemia, including frontline consolidation and relapsed or refractory disease.
blincytoRevenueAnnual revenue recognized from sales to Cardinal Health.
cardinalHealthRevenueAnnual revenue recognized from sales to Cencora, formerly AmerisourceBergen Corporation.
cencoraRevenueProduct sales of ENBREL, a tumor-necrosis-factor blocker Amgen markets in the United States and Canada primarily for rheumatoid arthritis, plaque psoriasis and psoriatic arthritis.
enbrelRevenueWorldwide product sales of EVENITY, Amgen's osteoporosis treatment for postmenopausal women at high risk of fracture and, in Japan, men at high fracture risk.
evenityRevenueUnited States product sales of KRYSTEXXA, the medicine Amgen acquired with Horizon for chronic refractory gout that remains uncontrolled by conventional treatment.
krystexxaRevenueProduct sales of KYPROLIS, Amgen's treatment used alone or in drug combinations for relapsed or refractory multiple myeloma after prior therapy.
kyprolisRevenueAnnual revenue recognized from sales to McKesson Corporation.
mckessonRevenueWorldwide product sales of Nplate, Amgen's treatment for low platelet counts in patients with immune thrombocytopenia who have not responded sufficiently to certain prior treatments.
nplateRevenueWorldwide product sales of Otezla, Amgen's oral therapy for plaque psoriasis, active psoriatic arthritis and oral ulcers associated with Behçet's disease.
otezlaRevenueProduct sales from Amgen products not separately identified in the product-sales breakdown.
otherProductsRevenueRevenue from sources other than product sales during the period.
otherRevenueTotal revenue from product sales during the period.
productRevenueWorldwide product sales of Prolia, Amgen's treatment for osteoporosis and other bone loss in patients at high fracture risk. It contains the same active ingredient as XGEVA but uses different indications, patients, dose and frequency.
proliaRevenueWorldwide product sales of Repatha, Amgen's PCSK9 inhibitor for lowering LDL cholesterol and reducing major cardiovascular-event risk in eligible adults.
repathaRevenueRevenue generated outside the United States during the period.
restOfWorldRevenueProduct sales of TEPEZZA, the IGF-1R-targeting antibody Amgen acquired with Horizon for the treatment of thyroid eye disease.
tepezzaRevenueWorldwide product sales of TEZSPIRE, the Amgen-AstraZeneca antibody approved for severe uncontrolled asthma and, in multiple markets, chronic rhinosinusitis with nasal polyps.
tezspireRevenueRevenue generated in the United States during the period.
unitedStatesRevenueWorldwide product sales of Vectibix, Amgen's therapy for wild-type RAS metastatic colorectal cancer and, in a U.S. combination regimen, previously treated KRAS G12C-mutated disease.
vectibixRevenueWorldwide product sales of XGEVA, Amgen's treatment for preventing fractures and other skeletal complications in patients with bone metastases from solid tumors or multiple myeloma. It contains the same active ingredient as Prolia but uses different indications, patients, dose and frequency.
xgevaRevenue